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Abstract 
Background: Transcatheter aortic valve implantation (TAVI) is associated with a high 
incidence of cerebrovascular injury. As these injuries are thought to be primarily embolic, 
neuroprotection strategies have focussed on embolic protection devices. However, the 
topographical distribution of cerebral emboli and how this impacts on the effectiveness of 
these devices has not been thoroughly assessed. Here, we evaluated the anatomical 
characteristics of magnetic resonance imaging (MRI)-defined cerebral ischaemic lesions 
occurring secondary to TAVI to enhance our understanding of the distribution of 
cardioembolic phenomena. 
Methods: Forty patients undergoing transfemoral TAVI with an Edwards SAPIEN-XT
TM
 
valve under general anaesthesia were enrolled prospectively in this observational study. 
Participants underwent brain MRI pre-procedure, and 3±1 days and 6±1 months post-
procedure.  
Results: Mean±standard deviation participant age was 82±7 years. Patients had an 
intermediate-to-high surgical risk, with a mean Society of Thoracic Surgeons score of 
6.3±3.5 and EuroSCORE of 18.1±10.6. Post-TAVI there were no clinically apparent 
cerebrovascular events but MRI assessments identified 83 new lesions across 19/31 (61%) 
participants, with a median±inter-quartile range number and volume of 1±2.8 lesions and 
20±190µL per patient. By volume, 80% of the infarcts were cortical, 90% in the posterior 
circulation and 81% in the right hemisphere. 
Conclusions: The distribution of lesions that we detected suggests that cortical grey matter, 
the posterior circulation, and the right hemisphere are all particularly vulnerable to 
perioperative cerebrovascular injury. This finding has implications for the use of 
intraoperative cerebral embolic protection devices, particularly those that leave the left 
subclavian and, therefore, left vertebral artery unprotected. 
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Introduction 
Transcatheter aortic valve implantation (TAVI) has revolutionised the management of severe 
aortic stenosis in patients at high surgical risk. However, neurological events remain a 
concerning complication with clinically apparent stroke occurring in as many as 9.1% of 
patients in the early postoperative period.
1,2
 Furthermore, the perioperative incidence of 
magnetic resonance imaging (MRI)-defined cerebral infarcts ranges from 58–91%.3-12  
 
The aetiology of neurological injury associated with TAVI is multifactorial but 
thromboembolic phenomena arising from the procedure are understood to be primarily 
responsible. An analysis of embolic protection devices removed following TAVI procedures 
found that 99% of filters contained embolic debris, including thrombus, calcification, valve 
tissue, arterial wall and foreign material.
2
 Thus, embolic protection devices have become the 
‘new frontier’ of both TAVI-related and perioperative neuroprotection research.  
 
As MRI-defined cerebral infarcts are common and can be objectively and specifically 
measuremed, they have become an accepted surrogate marker of perioperative cerebral 
embolisation and a recommended primary endpoint to determine neuroprotection device 
efficacy.
13, 14
 Although a number of studies have reported the incidence of these lesions 
following TAVI,
3-12
 few explore their anatomical distribution, which is essential for 
understanding emboli transport and the subsequent cerebral predilection for injury. Here, we 
used diffusion-weighted MRI (DWI) lesion number and volume to characterise the 
topographic pattern of cerebral ischaemic lesions following the TAVI procedure. The 
distribution that we identified not only extends our understanding of the causative 
mechanisms of cerebrovascular injury but also allows us to assess the effectiveness of current 
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neuroprotective strategies. 
Materials and Methods 
Study design and patient selection 
Prospective, consecutive screening was performed on all patients presenting to The Prince 
Charles Hospital in Brisbane, Australia for isolated TAVI using the SAPIEN-XT
TM
 (Edwards 
LifeSciences, Irvine, CA, USA) via a transfemoral approach between January and December 
2016. Each patient’s suitability for TAVI was determined by a multidisciplinary ‘heart team’, 
which included cardiologists (general, interventional, and imaging), a cardiothoracic surgeon, 
a cardiac anaesthetist, and nursing staff, as per international guidelines.
15
 In all patients, 
TAVI was performed under general anaesthesia, induced with propofol and maintained with 
sevoflurane, neuromuscular blockade (cisatracurium or rocuronium), and an ultra-/short-
acting opioid (remifentanil or fentanyl). Depth of anaesthesia was guided by Bispectral 
Analysis (BIS
TM
, Covidien, Dublin, Ireland). 
 
Before subject recruitment or data collection, ethics approval was obtained from the 
hospital’s Human Research Ethics Committee (HREC/12/QPCH/291). Informed consent was 
obtained from all participants prior to their enrolment in the study. All-comers were 
considered with exclusion criteria as follows: (1) pre-existing neurological impairment, as 
defined by a modified Rankin score of ≥3 (i.e., moderate disability, requiring some 
assistance, but able to mobilise independently); (2) previous cerebrovascular events 
(including stroke or transient ischaemic attack); (3) carotid artery stenosis >50% on duplex 
ultrasonography; (4) the presence of intra-cardiac thrombus identified on routinely performed 
pre-procedure transoesophageal echocardiograph; (5) any contraindication to magnetic 
resonance imaging (MRI), including incompatible metallic prosthesis or foreign body, the 
inability to lie flat, or claustrophobia requiring sedation; (6) poor to absent English-speaking 
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skills; and (7) prior aortic valve replacement.  
 
Imaging 
At baseline (within 24 hours prior to TAVI), an MRI of each patient’s brain was obtained 
using a 1.5-Tesla system (MAGNETOM Aera, Siemens Healthcare GmbH, Erlangen, 
Germany). These scans were used to assess cerebrovascular anatomy, identify significant 
intracranial stenosis, and grade degenerative changes in each patient. The Global Cortical 
Atrophy Scale (GCAS) was used to quantify the degree of cerebral atrophy,
16
 and the 
Fazekas scale to quantify T2 hyperintense lesions in periventricular white matter and deep 
white matter.
17
 Early follow-up MRI was performed on post-procedure day 3±1, and those 
who sustained cerebral infarction were followed-up with a repeat MRI at 6±1 months. The 
imaging protocol for the baseline assessment was comprehensive, consisting of standard fast-
spin echo sequences (T1-weighted and T2-weighted), DWI, apparent diffusion coefficient 
(ADC) mapping, susceptibility-weighted imaging (SWI), T2-weighted fluid-attenuated 
inversion recovery (FLAIR), and time of flight angiography of the Circle of Willis to 
document any pre-existing disease. The more limited follow-up scans comprised DWI, ADC, 
SWI, T2-weighted, T1-weighted, and FLAIR imaging. Cerebral ischaemia was defined by 
DWI hyperintensity caused by the restricted diffusion of water with reciprocal hypointensity 
on ADC maps.
18
 T1-weighted, T2-weighted, and FLAIR sequences were used to exclude 
other lesions that can mimic strokes. Lesions were quantified both by number and by volume, 
the latter using automated three-dimensional reconstructions from planimetry obtained by 
manual contouring (OsiriX, Geneva, Switzerland). To analyse their topographical 
distribution, lesions were stratified based on the type of brain parenchyma involved, 
hemisphere, and vascular territory (Figure 1).  
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Figure 1: Vascular territories of the brain. aa, arteries; ACA, indicates anterior cerebral artery; AICA, anterior 
inferior cerebellar artery; MCA, middle cerebral artery; PCA, posterior cerebral artery; PICA, posterior inferior 
cerebellar artery; SCA, superior cerebellar artery. © Kayama Studios 2016. 
 
Clinical assessment 
A detailed standardised medical history was obtained from each patient. Clinically apparent 
stroke was detected and localised using the National Institutes of Health Stroke Scale 
(NIHSS), whereas the modified Rankin Scale was used to categorise stroke severity. These 
tests were administered within 24 hours prior to the TAVI procedure, and again at 3±1 days, 
6±1 weeks, and 6±1 months post TAVI.  
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Statistical analysis 
The primary endpoint was new DWI-positive lesions on the post-procedure scan relative to 
baseline MRI, quantified by both number and volume (L).13, 18 Clinically apparent 
cerebrovascular events, including stroke (either major or minor) and transient ischaemic 
attack (TIA), were secondary endpoints. Summary statistics are presented as means±standard 
deviations (SD) when the data were parametric, or as medians±inter-quartile range (IQR) 
when non-parametric. Significance testing was performed for both: (1) the null hypothesis 
(N0) that distribution is equal (i.e., 50:50 between anterior:posterior circulations [P50:50]); and, 
(2) the N0 that the number of embolic lesions is proportional to blood flow, which is weighted 
70:30 anterior:posterior circulations [P70:30]). 
 
This study was funded by the Prince Charles Hospital Foundation in Brisbane, Australia; the 
National Heart Foundation, Australia; and the Health Innovation, Investment and Research 
Office, Office of the Director-General, Department of Health, Queensland Government, 
Australia. The authors are solely responsible for the design and conduct of this study, all 
study analyses, the drafting and editing of the paper and its final contents.  
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Results 
Patient and procedural characteristics 
Forty patients were enrolled between January and December 2016, and are included in this 
analysis. A flowchart of patients throughout the study is shown in Figure 2. Baseline patient 
and procedural characteristics are summarised in Table 1.
15
  
 
 
Figure 2: Flowchart of study participants. 
 
 
 
 
 
 
55 eligible patients consented
- Logistical difficulty obtaining baseline 
  assessments (n=7)
- Performed under local anesthetic (n=2)
- Different TAVI prosthesis implanted (n=3)
- Procedure cancelled or postponed (n=3)
31 patients underwent early 
(day 3±1) post-procedure MRI 
(primary endpoint)
 Baseline assessments and Edwards 
SAPIEN-XT implanted in 40 
patients
- Pacemaker (n=4)
- Medically unfit (n=1)
- Withdrew consent (n=2)
- Logistical difficulty obtaining 
  early post-procedure MRI (n=2)
21 patients underwent delayed
(6±1 month) post-procedure MRI 
- patients without evidence of 
  new cerebral infarction (n=10)
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Variable Measure 
Patient Characteristics (n=40) 
Age, years 82.3 ± 7 
Female 24 (58.5) 
Logistic EuroSCORE, % 18.06 ± 10.6 
STS score, % 6.27 ± 3.5 
BMI, kg/m
2
 28.8 ± 7.2 
Hypertension 32 (78%) 
Hyperlipidemia 36 (88%) 
Diabetes mellitus 16 (39%) 
Chronic renal impairment 12 (29%) 
Chronic lung disease 12 (29%) 
Significant (>5 pack year) smoking 18 (44%) 
Pre-operative LVEF 57.8 ± 14.05 
Atrial fibrillation 12 (29%) 
Procedural Characteristics 
Device success 38 (95%) 
Average procedure time, minutes 73.1 ± 35.9 
Average fluoroscopic time, minutes 14.2 ± 8.3 
Fluoroscopy contrast volume, mL 146 ± 50 
 
Table 1. Baseline characteristics. Values are expressed as mean ± SD or as n (%). Abbreviations: BMI, body 
mass index; LVEF, left ventricular ejection fraction; STS, Society of Thoracic Surgeons. 
 
Neurologic outcomes 
Baseline MRI 
Given the advanced age and moderate-to-high risk of the study population, it is not surprising 
that a degree of global cerebral atrophy was identified in all patients on baseline MRI (Figure 
3). In two patients, a subacute supratentorial infarct was detected: one exhibited a deep white 
matter infarct, and the other a cortical infarct. Convincing chronic MRI evidence of seven 
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prior infarctions was observed across five individuals. Focal SWI hypointensity was observed 
in the majority (32/40) of patients. A total of 90 lesions were identified, with a median of 
2±2.25 lesions per patient. In addition, SWI sequences identified gyriform superficial 
siderosis in three individuals and linear evidence of previous haemorrhagic change in an old 
infarct in another patient. One-quarter of the patients (10/40) had persistent foetal origins of 
their posterior cerebral arteries (PCAs), whereby the posterior communicating artery was 
greater in calibre than the ipsilateral P1 segment of the PCA. Incidental findings included a 
pituitary macroadenoma, a pontine cavernous angioma, a 4mm right internal carotid artery 
aneurysm, and the recurrence of a meningioma resected approximately two decades earlier. 
 
Figure 3: Radiological grading of degenerative changes using the Global Cortical Atrophy Scale (Global 
Atrophy), and Fazekas scores for periventricular white matter (PVH), and deep white matter (DWM). 
 
Post-procedural MRI 
Of the 40 participants who underwent a baseline MRI and received a SAPIEN-XT valve, 31 
were assessed for the primary endpoint (Figure 2). We identified 83 new DWI-positive 
lesions across 19/31 (61%) patients, a median of 1±2.8 lesions/patient, with a volume of 
20±190 μL/patient. In those 19 patients, typically more than one lesion was present (in 12/19 
cases; 63%). The distribution characteristics of these lesions are presented in Table 2 and 
Figure 4. Lesions typically involved the cortical grey matter by both number (50 lesions or 
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60%) and volume (9,327 μL or 80%) and 49 (59%) occurred in the posterior circulation and 
34 (41%) in the anterior circulation (P50:50 = 0.2; P70:30 < 0.0001). Similarly, when 
considering the total volume of infarction, 10,255 μL (90%) occurred in the posterior 
compared with 1,192 μL (10%) in the anterior circulation (P < 0.0001 for both N0). By 
number, 43 (63%) lesions occurred in the right hemisphere versus 25 (37%) lesions on the 
left (P = 0.06) totalling volumes of 9,250 μL (81%) and 2,150 μL (19%), respectively (P < 
0.0001). Importantly, cerebellar and brainstem lesions were not lateralised to the left or right 
as such stratification would confound our understanding of the distribution of cardiogenic 
emboli traversing the aorta and branches.  
 
Fifteen lesions demonstrated a T2-FLAIR or T1-weighted signal abnormality, which can be 
ascribed to the relatively small average infarct size to slice thickness. Four acute infarcts in 
three patients demonstrated new, associated SWI hypointensity consistent with haemorrhage. 
Eighteen new post-procedural SWI hypointensities were identified in ten patients, with a 
maximum of four new lesions per patient. Superficial linear gyral SWI hypointensity 
suggestive of low-volume subarachnoid haemorrhage was identified in one patient.  
 
Figure 4: Anatomical distribution of MRI-defined cerebral infarctions in three-dimensional views of the brain: 
A) sagittal, B) coronal, and C) axial. © Kayama Studios 2016. 
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Number of 
lesions 
P-value 
Total volume of 
lesions (μL) 
P-value 
Hemispheric Distribution (excluding cerebellum and brainstem) 
Right 43 (63%) 
0.06 
9250 (81%) 
<0.0001 
Left 25 (37%) 2150 (19%) 
Vascular Distribution 
Anterior 
Circulation 
34 (41%) 
0.2*; 
<0.0001
†
 
1192 (10%) 
<0.0001*
†
 
Posterior 
Circulation 
49 (59%) 10255 (90%) 
Brain Parenchyma 
Cortical Grey 50 (60%) 
 
9327 (80%) 
 
Subcortical Grey 3 (4%) 185 (2%) 
Subcortical White 15 (18%) 782 (7%) 
Cerebellar 13 (16%) 1106 (10%) 
Brainstem 2 (2%) 220 (2%) 
 
Table 2. Anatomical distribution of MRI-defined cerebral infarctions. * Based on the null hypothesis that 
emboli distribution is equal (i.e., 50:50); 
† 
Based on the null hypothesis that emboli distribution is proportional 
to blood flow (which is weighted 70:30 anterior:posterior).  
 
Six-month MRI 
All post-procedural DWI-positive lesions resolved by the 6-month MRI scan consistent with 
the natural evolution of DWI changes. Given the relatively small volumes of the infarcts, the 
majority of lesions were no longer reliably detectable on T2-FLAIR or T1-weighted 
sequences. One individual demonstrated new SWI hypointensity at an infarct site and three 
new SWI hypointensities were detected in another patient. A new linear superficial gyriform 
SWI hypointensity, consistent with blood products, in a third individual. Finally, a new acute 
left-frontal, deep white matter infarct was identified in an individual with advanced 
background white matter changes at baseline. 
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Objective clinical assessments 
No clinically apparent cerebrovascular events were detected. 
Discussion 
This analysis offers a unique opportunity to observe the distribution of cardiogenic 
microemboli and new ischaemic lesions post-TAVI. We identified 83 new lesions across 
19/31 (61%) participants, 80% of which by volume involved cortical grey matter, 90% 
occurred in the posterior circulation and of those occurring in the anterior circulation, 81% 
were in the right hemisphere. This topographical distribution raises several procedural and 
physiological questions for consideration.  
 
TAVI is associated with the frequent occurrence of cerebral ischaemic lesions, with reported 
incidence rates ranging from 58–98%.3-9, 19 The 61% incidence identified in this cohort is at 
the lower end of this range and could reflect the comparatively lower surgical risk of this 
sample and also the continual improvement in TAVI prostheses and procedures.
20
 Indeed, the 
SAPIEN-XT valve used in this study has now largely been superseded by a newer-generation 
iteration, the SAPIEN-3, which has demonstrated lower risk for cerebral infarction 
generation.
2
  
 
Considering vascular territories, significantly greater cerebral infarction was observed in the 
posterior versus anterior circulation with the PCA territory being the most vulnerable. This 
result is perhaps counter-intuitive as emboli should favour arteries that receive the largest 
volume of blood. The anterior cerebral circulation is formed by branches of the internal 
carotid arteries and in healthy awake patients contributes approximately 70% of the brain’s 
blood supply.
21
 The remaining 30% of cerebral blood flow arises from the two vertebral 
arteries, and this is the major supply for the posterior cerebral circulation. Based on blood 
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flow distribution, therefore, one-third of all cardiogenic emboli would be expected in the 
posterior circulation. Consistent with this, when considering all strokes, typically only 20–
25% of ischaemic events occur in the posterior circulation.
22
  
 
Blood-flow distribution during cerebrovascular stress is less clear. The influence of 
anaesthesia is of particular relevance but is poorly characterised with limited studies 
presenting conflicting data. Indeed, its effect is likely to be heterogeneous depending on the 
exact drugs, dosage and area of brain considered. Kaitsi  et al.
23
 identified a global reduction 
in cerebral blood flow (propofol > sevoflurane in equianaesthetic doses); however, significant 
dose-dependent regional differences were evident. For example, high doses (2 minimum 
alveolar concentration [MAC]) of sevoflurane concurrently caused noticeable increased 
cerebellar flow (38%) and reduced frontal flow (23%). Conversely, Rozet et al.
24
 using low 
dose sevoflurane anaesthesia (0.5 MAC) demonstrated that posterior circulation blood flow 
was reduced relative to the anterior circulation. 
 
Inextricably linked to cerebral blood flow are the cerebral autoregulation and neurovascular 
coupling mechanisms that defend the brain against haemodynamic and metabolic 
disturbance. Impaired autoregulation may result in relative hyper- or hypoperfusion, either of 
which could be detrimental. Specifically, increased blood flow might deliver more emboli, 
whereas reduced blood flow could magnify the effects of microemboli by impairing their 
washout.
25
 Thus relatively impaired cerebral autoregulation in the posterior versus anterior 
circulation is a plausible explanation for the observed differences in vulnerability to injury. 
This is supported by the findings that (1) the posterior circulation has lower carbon dioxide 
reactivity than the anterior circulation,
26
 and (2) there is impaired dampening of arterial blood 
pressure oscillations in the posterior versus the anterior circulation.
27
 Again, the role of 
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anaesthesia is unclear with Rozet et al.
24
 providing the only data and in only low dose 
sevoflurane (0.5 MAC) anaesthesia where cerebrovascular reactivity was maintained in both 
anterior and posterior circulations.  
 
Anatomical differences also exist between the anterior and posterior circulations and may 
contribute to or explain some of the abovementioned physiological characteristics and 
vulnerability of the posterior circulation. Fluorescence microscopy of adult human brain 
tissue has identified differences in sympathetic innervation of the anterior versus posterior 
cerebral arteries with clear implication for vascular tone and autoregulatory capacity.
28
 
Furthermore, insult / injury may be exacerbated by intracranial atherosclerosis, which is more 
prone to occur in the posterior than anterior circulation, with the basilar artery being the 
single most common site.
29
 The tortuous path of the vertebral arteries and acutely angled 
branches of the basilar artery might exacerbate this predilection further (Figure 5). 
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Figure 5: Anatomy of the cerebral circulation. R indicates right; L, left; a, artery; aa, arteries; ACA, anterior 
cerebral artery; AICA, anterior inferior cerebellar artery; MCA, middle cerebral artery; PCA, posterior cerebral 
artery; aa, arteries; PICA, posterior inferior cerebellar artery; SCA, superior cerebellar artery. © Kayama 
Studios 2016. 
 
Alternatively, the distribution of cerebral infarcts may reflect differences in distribution of 
embolic load / insult rather than innate regional anatomical or physiological differences. 
Sophisticated modelling has shown a size-dependent trajectory for cardiogenic emboli 
reaching the carotid and vertebral arteries that varies distinctly from what is expected based 
on blood flow distribution.
30
 In particular, the preponderance of small to medium-sized 
cardiogenic particles reaching the branch arteries of the aortic arch, and subsequently the 
carotid and vertebral arteries, was markedly greater than that expected using volumetric 
flow.
30
 However, further stratification of emboli between the carotid and vertebral arteries 
was not assessed.  
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A preponderance of clinically apparent infarctions in the posterior regions of the brain in 
patients undergoing cardiac surgery
31-35
 and TAVI
3, 4, 7
 has been noted previously, albeit not 
consistently.
5, 8-11
 Cassie et al also documented this predilection experimentally. In a supine 
canine model and using an antifoam solution to perfuse the aorta, these investigators 
identified a significantly greater number of emboli and infarcts in the cerebellum, brainstem, 
and occipital lobes.
36
  
 
Logically, the effects of gravity must also be considered in supine patients who receive large 
doses (average 140mL in our patient cohort) of iodinated radio-contrast during fluoroscopy. 
The density of radio-contrast used in this setting is greater than that of whole blood, a 
characteristic that is essential to its utility. Consequently, it is feasible that a contrast bolus 
might preferentially pool posteriorly in a supine patient, thereby reducing the oxygen-
carrying capacity of the blood or drawing disproportionate emboli. However, this postulation 
is purely speculative. 
 
In our patient cohort, the right hemisphere seemed to be more vulnerable than the left, 
accounting for 63% of the ischaemic lesions by number (P50:50=0.06; P70:30 < 0.0001) and 
81% by volume (P<0.0001 for both N0). This is contrary to other TAVI studies, in which 
lesions were predominately in the left cerebral hemisphere.
4, 6, 8, 9
 The left-sided vulnerability 
observed in these early studies was proposed to result from exposure of the left common 
carotid to emboli dislodged from the aortic arch during the placement and use of catheters 
and associated devices. However, transcranial Doppler studies have reported the majority of 
embolic signals arising while the TAVI prosthesis is being positioned and implanted and 
have concluded that the major source of embolic burden is the aortic valve itself.
37
 It is 
important to recognise that embolic signals as measured by transcranial Doppler in this study 
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did not discriminate the nature or size of embolic material or indicate a threshold for emboli 
sufficient to cause infarction.  
 
The right-sided vulnerability that we observe seems more logical because as cardiogenic 
emboli traverse the aortic arch, the innominate artery supplying the right hemisphere is the 
first to be encountered; thus, it is exposed to the total embolic load whereas subsequent 
supra-aortic arch vessels are exposed to a lesser load. Furthermore, anatomically, the 
innominate artery is of larger calibre and traverses a course parallel to the ascending aorta, 
contrary to the left carotid artery, which is smaller and arises perpendicular to the aortic 
arch.
38
  
 
We identified 60% of the lesions by number and 80% by volume in the cortical grey matter. 
Although the threshold for ischaemia is often considered and reported on a whole-brain basis, 
tissue-specific differences support increased vulnerability of grey over white matter. Perhaps 
most evident are differences in the cellular constituents and, therefore, metabolic 
requirements and blood flow,
39
 as well as well-documented differences in neurochemical 
responses to ischaemia.
40
 MRI studies have also established a significantly lower ischaemic 
threshold in grey versus white matter, with a cut-off for cerebral blood flow of 35 versus 20 
mL/100 g/min (P < 0.0001) and a cerebral blood volume of 1.7 versus 1.2 mL/100 g, 
respectively (P < 0.0001).
41
 Consequently, grey matter has greater blood flow and volume, 
and a shorter mean transit time than white matter; thus, the former may be exposed to greater 
embolic loads and be more vulnerable to hypoperfusion. 
 
The topographical distribution of new ischaemic lesions that we observed has implications 
for neuroprotection during TAVI. Studies to date suggest that embolic protection devices 
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represent a promising adjunct for improving the safety of TAVI. Recently published 
randomised controlled trials of the Sentinel
TM
 Cerebral protection System [Claret Medical, 
Santa Rosa, CA, USA] have shown a reduction in the volume of MRI-detected cerebral 
infarction in vascular territories protected by embolic protection devices resulting in FDA 
approval.
2, 19, 42-44
 However, this and other cerebral protection devices – e.g., the EmbrellaTM 
embolic deflector system [Edwards Lifesciences Ltd., Irvine, CA, USA] – are inefficient at 
protecting the left subclavian artery (Figure 6). This is the origin of the left vertebral artery, 
which merges with the right vertebral artery to form the basilar artery – the major supply to 
the posterior portion of the Circle of Willis (Figure 5). Thus, embolic protection devices that 
lack coverage of the left subclavian artery also fail to completely protect the posterior 
circulation resulting in 19 of 28 vascular territories and 26% of the brain volume being either 
partially or completely unprotected.
19
 Our findings highlight this territory as one of the most 
vulnerable to ischaemic lesions suggesting that, although technically challenging, the 
development of embolic protection devices that offer full coverage of all three supra-aortic 
branches of the aortic arch may be beneficial.  
 
Figure 6: Embolic protection devices. A) Embrella
TM
 Deflector (Edwards LifeSciences, Irvine, CA, USA); B) 
Sentinel
TM
 cerebral protection system (Claret Medical, Santa Rosa, CA, USA); C) Triguard
TM
 Cerebral 
Deflector (Keystone Heart Ltd, Caesarea, IL, USA). Reprinted from Fanning et al.
1
with permission of the 
publisher. © 2014, Elsevier, Inc.   
 
Our study involved only a relatively small, nonrandomised patient cohort and all the TAVI 
A. B. C.
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procedures were performed exclusively using the Edwards SAPIEN-XT
TM
 prosthesis, 
limiting extrapolation of these findings to newer iterations of TAVI prostheses or other 
cardiac procedures. Furthermore, the risk stratum of our cohort was heterogeneous, with a 
mixture of intermediate-risk, high-risk, and inoperable participants. Although comparing 
differences in surgical risk strata is prudent, this was not possible for our cohort. The limited 
sample size and high incidence of DWI-positive lesions also affected our ability to perform 
more sophisticated logistic regression analysis. DWI and neurologic assessments were 
performed conscientiously, however, they were only possible in those patients able to tolerate 
them. Several of our TAVI patients were unable to undergo follow-up scans due to frailty, 
being medically unfit, or pacemaker insertion, which could have introduced further bias. 
Consequently, only 31/40 (78%) of patients who underwent baseline assessment were 
followed up with the day 3±1 scan and of these 21/31 (68%) underwent the 6-month MRI. 
Finally, inter-study methodological heterogeneity pervades this field of research and must be 
considered when placing this into the context of previous work.  
 
Conclusions 
Our understanding of periprocedural cardioembolic strokes that occur secondary to cardiac 
interventions is less developed than one might think, and a number of vital questions remain 
unanswered. In our cohort of patients undergoing TAVI, we identified the posterior 
circulation and the right hemisphere as particularly vulnerable to cerebral infarctions. These 
findings contrast with previous reports but are consistent with our knowledge of 
cardioembolic stroke in theoretical models and other cardiac procedures. Certainly, this has 
implications for risk-minimisation strategies, particularly when evaluating protective devices 
designed to prevent the spread of emboli into the cerebral circulation. This is a pertinent issue 
given the extension of the TAVI procedure to lower-risk patients who have a longer life 
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expectancy and thus more time for subclinical neurological injury to exert adverse effects. 
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